Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPRING1 pseudogene 3 is a transcribed DNA segment classified as a pseudogene of the SPRING1 (SREBF pathway regulator in Golgi 1) gene[1][7]. Pseudogenes such as SPRING1P3 are genomically similar to their functional parent genes but typically do not produce functional protein products. While the parental SPRING1 gene is involved in the regulation of the SREBP signaling pathway, SPRING1P3 itself does not have a confirmed protein-coding function or therapeutic target status[1][7]. The general functional potential of pseudogenes includes possible regulatory roles through their RNA transcripts, such as competing for regulatory microRNAs (miRNAs) or affecting stability of messenger RNAs, but no direct evidence exists for SPRING1P3’s functional role or involvement in disease[3][6][7]. No evidence exists linking SPRING1P3 to therapeutic targeting, disease causality, or drug interaction[1][7]. SPRING1P3 should be considered a genomic pseudogene and not a direct therapeutic target or functional receptor/protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPRING1 pseudogene 3 (SPRING1P3).